Marker Therapeutics: lymphodepletion improves MT-601 cell expansion; enrollment surging

Marker Therapeutics, Inc.

Phase 1 APOLLO study data: TCR sequencing shows MT-601 clones expanded/persisted at higher levels with lymphodepletion.
Prior data (Dec 2024): 7/9 patients (78%) objective response, 4 complete responses (44.4%); no DLTs or ICANS.
In first 5 months of 2025, enrolled and manufactured product for more patients than in all of 2024.
Company expects clinical data readout from APOLLO study later this year.
MT-601 targets lymphoma patients who relapsed after anti-CD19 CAR-T or for whom CAR-T is not an option.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.